Daily Stock Analysis, DXD, DEXCOM INC, priceseries

DEXCOM INC. Daily Stock Analysis
Stock Information
Open
46.74
Close
48.55
High
48.59
Low
46.66
Previous Close
46.40
Daily Price Gain
2.15
YTD High
50.50
YTD High Date
Feb 24, 2022
YTD Low
39.10
YTD Low Date
Jan 5, 2022
YTD Price Change
8.65
YTD Gain
21.68%
52 Week High
57.50
52 Week High Date
Mar 8, 2021
52 Week Low
39.10
52 Week Low Date
Jan 5, 2022
52 Week Price Change
-8.05
52 Week Gain
-14.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 4. 2018
153.42
Dec 27. 2018
178.94
15 Trading Days
16.64%
Link
LONG
Feb 21. 2020
108.18
Mar 4. 2020
120.26
8 Trading Days
11.17%
Link
LONG
Mar 5. 2020
128.80
Mar 24. 2020
179.49
13 Trading Days
39.36%
Link
Company Information
Stock Symbol
DXD
Exchange
NASDAQ
Company URL
http://www.dexcom.com
Company Phone
8582000200
CEO
Kevin Ronald Sayer
Headquarters
California
Business Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001093557
About

Description

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.